Squamous cell carcinoma of the head and neck (HNSCC) represents a biologically and clinically heterogeneous group of malignancies with significant global ...
Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...
Patients who received neoadjuvant systemic therapy followed by surgical resection for mucosal HNSCC in the US National Cancer Database (2004-2022) were evaluated using 1:5 propensity score matching to ...
ctDNA-based clinicogenomic analysis of advanced head and neck cancer patients treated with immune checkpoint inhibitors. Assessing the safety and efficacy of GT201: A first-in-class autologous ...
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall ...
Head and neck cancers, particularly those originating in the oral cavity, have historically been attributed to well-defined etiological factors like ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...
Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...
Despite a higher incidence of poor outcomes with squamous cell carcinoma tumors on the scalp, it was the lip and temple that emerged as highest risk after adjustments for other factors.
There are three common types of skin cancer in the United States: basal cell carcinoma, squamous cell carcinoma and melanoma. Merkel cell carcinoma is a rare type of skin cancer. Fred Hutch Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results